ASCENDIS HEALTH LIMITED - Trading statement for the year ended 30 June 2023

Trading statement for the year ended 30 June 2023

Ascendis Health Limited
(Incorporated in the Republic of South Africa)
(Registration number: 2008/005856/06)
Share code: ASC
ISIN: ZAE000185005
(“Ascendis” or “the Company”)


TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2023


In terms of the Listings Requirements of the JSE Limited, a listed company is required to publish a
trading statement as soon as a reasonable degree of certainty exists that the financial results for the
period to be reported on next will differ by 20% or more from the financial results for the previous
published corresponding period.

Accordingly, the board of directors of Ascendis advises shareholders that it is reasonably certain that
the financial results for the year ended 30 June 2023 (“Current Period”), when compared with the
published results for the year ended 30 June 2022 (“Prior Corresponding Period”), are expected to
differ as follows:

Continuing Operations:

   -   loss per share from continuing operations will be between 42.5 cents and 51.9 cents,
       representing an improvement of between 73.1% and 67.2% compared to the restated loss per
       share from continuing operations of 158.2 cents reported for the prior corresponding period;

   -   headline loss per share from continuing operations will be between 37.4 cents and 45.7 cents,
       representing an improvement of between 69.5% and 62.7% compared to the restated headline
       loss per share from continuing operations of 122.4 cents reported for the prior corresponding
       period; and

Total Operations:

   -   earnings per share will be between 11.2 cents and 13.7 cents, representing a decrease of
       between 88.1% and 85.4% compared to the restated earnings per share from total operations
       of 93.6 cents reported for the prior corresponding period; and

   -   headline loss per share will be between 35.7 cents and 43.6 cents, representing an
       improvement of between 55.8% and 46.0% compared to the restated headline loss per share
       from total operations of 80.8 cents reported for the prior corresponding period.

This trading statement is the responsibility of the directors and the financial information on which this
statement is based has not been reviewed or reported on by the external auditors of the Company.

The expected publication date of the Company’s annual results is 29 September 2023.

Footnotes:
^ The weighted average number of shares outstanding for the period ended 30 June 2023 has been
retrospectively restated in accordance with IAS 33 (par.27(b),28,64).
Johannesburg
26 September 2023

Sponsor
Valeo Capital (Pty) Ltd

Date: 26-09-2023 02:32:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.